Symbols / SRZN $33.03 +6.21% Surrozen, Inc.
SRZN Chart
About
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Market Cap | 388.52M | Enterprise Value | 296.80M | Income | -242.03M | Sales | 3.48M | Book/sh | -19.21 | Cash/sh | 7.77 |
| Dividend Yield | — | Payout | 0.00% | Employees | 44 | IPO | — | P/E | — | Forward P/E | -9.27 |
| PEG | — | P/S | 111.74 | P/B | -1.72 | P/C | — | EV/EBITDA | -7.14 | EV/Sales | 85.36 |
| Quick Ratio | 9.01 | Current Ratio | 9.22 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -32.37 | EPS next Y | -3.56 |
| EPS Growth | — | Revenue Growth | -19.40% | Earnings | 2026-03-23 | ROA | -35.75% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -23.94% | Profit Margin | 0.00% | Shs Outstand | 11.76M | Shs Float | 5.42M | Short Float | 5.52% |
| Short Ratio | 3.73 | Short Interest | — | 52W High | 33.96 | 52W Low | 5.90 | Beta | 0.52 | Avg Volume | 121.29K |
| Volume | 218.49K | Target Price | $38.75 | Recom | None | Prev Close | $31.10 | Price | $33.03 | Change | 6.21% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-21 | init | TD Cowen | — → Buy | — |
| 2026-03-24 | reit | Cantor Fitzgerald | Overweight → Overweight | $40 |
| 2026-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2026-02-19 | init | Cantor Fitzgerald | — → Overweight | $40 |
| 2025-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-04-02 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-01-30 | init | HC Wainwright & Co. | — → Buy | $32 |
| 2025-01-03 | up | Guggenheim | Neutral → Buy | $45 |
- SRZN (Surrozen Inc.) posts wide Q3 2025 earnings miss and steep revenue drop, while shares rise modestly in today’s trading. - Revision Downgrade - UBND thành phố Hải Phòng hu, 23 Apr 2026 04
- Analysts’ Top Healthcare Picks: Surrozen (SRZN), Establishment Labs Holdings (ESTA) - The Globe and Mail Wed, 22 Apr 2026 09
- Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? - Yahoo Finance ue, 14 Apr 2026 07
- Surrozen director Kutzkey buys $3.99 million in SRZN stock - Investing.com ue, 02 Dec 2025 08
- SRZN Stock Analysis: Surrozen Inc Biotech 2% Dip and $27.87 Price Level Review - Cổng thông tin điện tử Tỉnh Sơn La Fri, 03 Apr 2026 07
- Surrozen (SRZN) EVP Li Yang donates 1,666 common shares in Form 4 - Stock Titan Wed, 01 Apr 2026 07
- SRZN (Surrozen Inc.) posts wide Q3 2025 earnings miss and steep revenue drop, while shares rise modestly in today’s trading. - Competitive Advantage - Xã Thanh Hà hu, 23 Apr 2026 00
- $SRZN stock is up 18% today. Here's what we see in our data. - Quiver Quantitative ue, 25 Nov 2025 08
- TD Cowen initiates Surrozen stock coverage with buy rating By Investing.com - Investing.com South Africa ue, 21 Apr 2026 10
- Is Surrozen (SRZN) Stock Testing Resistance | Price at $28.57, Up 2.53% - Earnings Season - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- Insider Purchase: Director at $SRZN Buys 148,150 Shares | SRZN Stock News - Quiver Quantitative Wed, 03 Dec 2025 08
- TCG Crossover funds boost Surrozen (SRZN) stake with open-market buys - Stock Titan Wed, 25 Mar 2026 07
- Column group buys Surrozen (SRZN) shares for $641,597 - Investing.com ue, 20 Jan 2026 08
- $5M milestone moves Surrozen toward an eye drug IND filing - Stock Titan Mon, 23 Mar 2026 07
- Insider Stock Purchases: March 26, 2026 - Quiver Quantitative hu, 26 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
3.48
-67.37%
|
10.65
|
0.00
-100.00%
|
12.50
|
| Operating Revenue |
|
3.48
-67.37%
|
10.65
|
0.00
-100.00%
|
12.50
|
| Operating Expense |
|
45.57
+25.90%
|
36.19
-15.88%
|
43.03
-24.30%
|
56.84
|
| Research And Development |
|
29.36
+38.96%
|
21.13
-22.39%
|
27.23
-26.43%
|
37.01
|
| Selling General And Administration |
|
16.20
+7.58%
|
15.06
-4.66%
|
15.80
-20.32%
|
19.83
|
| General And Administrative Expense |
|
16.20
+7.58%
|
15.06
-4.66%
|
15.80
-20.32%
|
19.83
|
| Other Gand A |
|
16.20
+7.58%
|
15.06
-4.66%
|
15.80
-20.32%
|
19.83
|
| Total Expenses |
|
45.57
+25.90%
|
36.19
-15.88%
|
43.03
-24.30%
|
56.84
|
| Operating Income |
|
-42.09
-64.81%
|
-25.54
+40.65%
|
-43.03
+2.96%
|
-44.34
|
| Total Operating Income As Reported |
|
-42.09
-64.81%
|
-25.54
+44.21%
|
-45.78
-3.25%
|
-44.34
|
| EBITDA |
|
-41.55
-72.45%
|
-24.10
+41.39%
|
-41.12
+2.99%
|
-42.38
|
| Normalized EBITDA |
|
135.09
+660.60%
|
-24.10
+37.19%
|
-38.37
+9.48%
|
-42.38
|
| Reconciled Depreciation |
|
0.54
-62.76%
|
1.44
-24.54%
|
1.91
-2.25%
|
1.96
|
| EBIT |
|
-42.09
-64.81%
|
-25.54
+40.65%
|
-43.03
+2.96%
|
-44.34
|
| Total Unusual Items |
|
-176.64
|
0.00
+100.00%
|
-2.75
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-176.64
|
0.00
+100.00%
|
-2.75
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-2.75
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
2.75
|
0.00
|
| Net Income |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Pretax Income |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Net Non Operating Interest Income Expense |
|
3.02
+78.38%
|
1.69
-27.65%
|
2.34
+199.62%
|
0.78
|
| Net Interest Income |
|
3.02
+78.38%
|
1.69
-27.65%
|
2.34
+199.62%
|
0.78
|
| Interest Income Non Operating |
|
3.02
+78.38%
|
1.69
-27.65%
|
2.34
+199.62%
|
0.78
|
| Interest Income |
|
3.02
+78.38%
|
1.69
-27.65%
|
2.34
+199.62%
|
0.78
|
| Other Income Expense |
|
-202.95
-410.99%
|
-39.72
-1587.26%
|
-2.35
-131.16%
|
7.55
|
| Other Non Operating Income Expenses |
|
-26.31
+33.75%
|
-39.72
-10079.40%
|
0.40
-94.73%
|
7.55
|
| Gain On Sale Of Security |
|
-176.64
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Net Income From Continuing And Discontinued Operation |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Net Income Continuous Operations |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Normalized Income |
|
-65.38
-2.86%
|
-63.56
-57.77%
|
-40.29
-11.90%
|
-36.00
|
| Net Income Common Stockholders |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Diluted EPS |
|
-32.37
-49.38%
|
-21.67
-1.59%
|
-21.33
-36.73%
|
-15.60
|
| Basic EPS |
|
-32.37
-49.38%
|
-21.67
-1.59%
|
-21.33
-36.73%
|
-15.60
|
| Basic Average Shares |
|
7.48
+154.96%
|
2.93
+45.34%
|
2.02
-12.82%
|
2.31
|
| Diluted Average Shares |
|
7.48
+154.96%
|
2.93
+45.34%
|
2.02
-12.82%
|
2.31
|
| Diluted NI Availto Com Stockholders |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
98.73
+103.70%
|
48.47
+5.18%
|
46.08
-48.48%
|
89.44
|
| Current Assets |
|
91.56
+135.18%
|
38.93
-5.35%
|
41.13
-49.41%
|
81.31
|
| Cash Cash Equivalents And Short Term Investments |
|
89.25
+158.19%
|
34.56
-4.10%
|
36.04
-52.47%
|
75.84
|
| Cash And Cash Equivalents |
|
89.25
+158.19%
|
34.56
-4.10%
|
36.04
+45.98%
|
24.69
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
51.15
|
| Receivables |
|
0.21
-91.81%
|
2.54
+18.08%
|
2.15
+8.80%
|
1.98
|
| Accounts Receivable |
|
0.00
-100.00%
|
2.04
-5.25%
|
2.15
+8.80%
|
1.98
|
| Prepaid Assets |
|
2.11
+15.33%
|
1.83
-22.53%
|
2.36
-13.76%
|
2.73
|
| Other Current Assets |
|
—
|
0.67
+15.69%
|
0.58
-23.28%
|
0.76
|
| Total Non Current Assets |
|
7.17
-24.83%
|
9.54
+92.70%
|
4.95
-39.14%
|
8.13
|
| Net PPE |
|
6.43
-23.08%
|
8.36
+116.77%
|
3.86
-44.07%
|
6.90
|
| Gross PPE |
|
14.81
-8.65%
|
16.21
+44.40%
|
11.23
-38.50%
|
18.25
|
| Accumulated Depreciation |
|
-8.38
-6.73%
|
-7.85
-6.50%
|
-7.37
+35.11%
|
-11.36
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
3.27
|
| Machinery Furniture Equipment |
|
0.52
+0.00%
|
0.52
-0.39%
|
0.52
+23.92%
|
0.42
|
| Other Properties |
|
13.18
-9.62%
|
14.58
+51.98%
|
9.59
-11.05%
|
10.78
|
| Leases |
|
1.12
+0.00%
|
1.12
+0.00%
|
1.12
-84.17%
|
7.05
|
| Investments And Advances |
|
—
|
—
|
—
|
0.00
|
| Other Non Current Assets |
|
0.73
-27.97%
|
1.02
-6.51%
|
1.09
-11.53%
|
1.23
|
| Total Liabilities Net Minority Interest |
|
286.49
+310.17%
|
69.85
+757.54%
|
8.14
-39.37%
|
13.43
|
| Current Liabilities |
|
9.93
+35.75%
|
7.32
+2.34%
|
7.15
-26.55%
|
9.73
|
| Payables And Accrued Expenses |
|
8.35
+57.71%
|
5.29
+21.47%
|
4.36
-37.05%
|
6.92
|
| Payables |
|
0.73
+137.91%
|
0.31
-41.71%
|
0.53
-20.21%
|
0.66
|
| Accounts Payable |
|
0.73
+137.91%
|
0.31
-41.71%
|
0.53
-20.21%
|
0.66
|
| Current Accrued Expenses |
|
7.62
+52.80%
|
4.99
+30.13%
|
3.83
-38.82%
|
6.27
|
| Current Debt And Capital Lease Obligation |
|
1.29
-29.47%
|
1.83
-26.75%
|
2.50
+12.17%
|
2.23
|
| Current Capital Lease Obligation |
|
1.29
-29.47%
|
1.83
-26.75%
|
2.50
+12.17%
|
2.23
|
| Other Current Liabilities |
|
0.29
+51.31%
|
0.19
-34.59%
|
0.29
-49.74%
|
0.58
|
| Total Non Current Liabilities Net Minority Interest |
|
276.56
+342.27%
|
62.53
+6172.02%
|
1.00
-73.07%
|
3.70
|
| Long Term Debt And Capital Lease Obligation |
|
5.35
-19.44%
|
6.64
+652.83%
|
0.88
-73.87%
|
3.38
|
| Long Term Capital Lease Obligation |
|
5.35
-19.44%
|
6.64
+652.83%
|
0.88
-73.87%
|
3.38
|
| Other Non Current Liabilities |
|
158.66
|
—
|
—
|
—
|
| Stockholders Equity |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Common Stock Equity |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
9.77
+199.65%
|
3.26
+58.12%
|
2.06
+2.85%
|
2.01
|
| Ordinary Shares Number |
|
9.77
+199.65%
|
3.26
+58.12%
|
2.06
+2.85%
|
2.01
|
| Additional Paid In Capital |
|
339.52
+28.67%
|
263.88
+1.64%
|
259.63
+1.86%
|
254.90
|
| Retained Earnings |
|
-527.28
-84.84%
|
-285.26
-28.67%
|
-221.69
-24.09%
|
-178.65
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-0.24
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-0.24
|
| Total Equity Gross Minority Interest |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Total Capitalization |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Working Capital |
|
81.63
+158.18%
|
31.62
-6.97%
|
33.98
-52.52%
|
71.57
|
| Invested Capital |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Total Debt |
|
6.64
-21.61%
|
8.47
+150.64%
|
3.38
-39.68%
|
5.60
|
| Capital Lease Obligations |
|
6.64
-21.61%
|
8.47
+150.64%
|
3.38
-39.68%
|
5.60
|
| Net Tangible Assets |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Tangible Book Value |
|
-187.76
-778.21%
|
-21.38
-156.36%
|
37.94
-50.09%
|
76.00
|
| Available For Sale Securities |
|
—
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
112.55
+101.37%
|
55.89
+48501.74%
|
0.12
-64.72%
|
0.33
|
| Duefrom Related Parties Current |
|
0.21
-58.57%
|
0.50
|
0.00
|
—
|
| Financial Assets |
|
0.00
-100.00%
|
0.15
|
0.00
|
—
|
| Investmentin Financial Assets |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-30.24
-71.57%
|
-17.63
+56.33%
|
-40.36
+8.57%
|
-44.15
|
| Cash Flow From Continuing Operating Activities |
|
-30.24
-71.57%
|
-17.63
+56.33%
|
-40.36
+8.57%
|
-44.15
|
| Net Income From Continuing Operations |
|
-242.03
-280.76%
|
-63.56
-47.68%
|
-43.04
-19.55%
|
-36.00
|
| Depreciation Amortization Depletion |
|
0.54
-62.76%
|
1.44
-24.54%
|
1.91
-2.25%
|
1.96
|
| Depreciation |
|
—
|
—
|
1.91
-2.25%
|
1.96
|
| Depreciation And Amortization |
|
0.54
-62.76%
|
1.44
-24.54%
|
1.91
-2.25%
|
1.96
|
| Other Non Cash Items |
|
72.12
+5167.79%
|
1.37
+7.54%
|
1.27
-19.79%
|
1.59
|
| Stock Based Compensation |
|
3.83
-6.78%
|
4.11
-5.90%
|
4.37
-3.21%
|
4.52
|
| Asset Impairment Charge |
|
0.92
|
0.00
-100.00%
|
0.17
|
0.00
|
| Operating Gains Losses |
|
131.22
+229.31%
|
39.85
+10449.87%
|
-0.39
+95.12%
|
-7.89
|
| Gain Loss On Investment Securities |
|
131.22
+230.24%
|
39.73
+18931.28%
|
-0.21
+97.33%
|
-7.89
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
-100.00%
|
0.11
+164.94%
|
-0.17
|
—
|
| Change In Working Capital |
|
3.15
+477.15%
|
-0.84
+78.72%
|
-3.93
+53.33%
|
-8.42
|
| Change In Receivables |
|
2.33
+564.74%
|
-0.50
|
0.00
+100.00%
|
-1.98
|
| Changes In Account Receivables |
|
2.33
+564.74%
|
-0.50
|
0.00
+100.00%
|
-1.98
|
| Change In Prepaid Assets |
|
-0.07
-106.03%
|
1.11
+21.42%
|
0.92
+1930.00%
|
-0.05
|
| Change In Payables And Accrued Expense |
|
2.65
+219.44%
|
0.83
+130.86%
|
-2.68
+29.76%
|
-3.82
|
| Change In Accrued Expense |
|
2.50
+137.03%
|
1.06
+141.41%
|
-2.55
-43.10%
|
-1.78
|
| Change In Payable |
|
0.14
+162.28%
|
-0.23
-71.43%
|
-0.13
+93.47%
|
-2.04
|
| Change In Account Payable |
|
0.14
+162.28%
|
-0.23
-71.43%
|
-0.13
+93.47%
|
-2.04
|
| Change In Other Current Assets |
|
0.07
+1.41%
|
0.07
+14.52%
|
0.06
+116.36%
|
-0.38
|
| Change In Other Current Liabilities |
|
-1.83
+21.93%
|
-2.34
-5.44%
|
-2.22
-1.46%
|
-2.19
|
| Investing Cash Flow |
|
-0.13
-392.31%
|
-0.03
-100.05%
|
51.72
+35.02%
|
38.31
|
| Cash Flow From Continuing Investing Activities |
|
-0.13
-392.31%
|
-0.03
-100.05%
|
51.72
+35.02%
|
38.31
|
| Net PPE Purchase And Sale |
|
-0.13
-392.31%
|
-0.03
+93.47%
|
-0.40
+45.33%
|
-0.73
|
| Purchase Of PPE |
|
-0.13
-392.31%
|
-0.03
+93.47%
|
-0.40
+45.33%
|
-0.73
|
| Capital Expenditure |
|
-0.13
-392.31%
|
-0.03
+93.47%
|
-0.40
+45.33%
|
-0.73
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
52.12
+33.52%
|
39.04
|
| Purchase Of Investment |
|
—
|
0.00
+100.00%
|
-28.04
+5.26%
|
-29.60
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
80.17
+16.80%
|
68.64
|
| Financing Cash Flow |
|
85.05
+425.79%
|
16.18
+5760.87%
|
0.28
+110.76%
|
-2.56
|
| Cash Flow From Continuing Financing Activities |
|
85.05
+425.79%
|
16.18
+5760.87%
|
0.28
+110.76%
|
-2.56
|
| Net Common Stock Issuance |
|
83.78
+422.22%
|
16.04
+401175.00%
|
-0.00
+99.85%
|
-2.61
|
| Common Stock Payments |
|
—
|
0.00
+100.00%
|
-0.00
+99.85%
|
-2.61
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-0.00
+99.85%
|
-2.61
|
| Proceeds From Stock Option Exercised |
|
1.27
+856.39%
|
0.13
-52.50%
|
0.28
+566.67%
|
0.04
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.10
|
| Changes In Cash |
|
54.68
+3799.59%
|
-1.48
-112.70%
|
11.64
+238.51%
|
-8.40
|
| Beginning Cash Position |
|
35.25
-4.02%
|
36.73
+46.37%
|
25.09
-25.08%
|
33.50
|
| End Cash Position |
|
89.93
+155.11%
|
35.25
-4.02%
|
36.73
+46.37%
|
25.09
|
| Free Cash Flow |
|
-30.37
-72.04%
|
-17.65
+56.69%
|
-40.76
+9.16%
|
-44.87
|
| Amortization Of Securities |
|
—
|
0.00
+100.00%
|
-0.73
-777.78%
|
0.11
|
| Common Stock Issuance |
|
83.78
+422.22%
|
16.04
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
83.78
+422.22%
|
16.04
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-01 View
- 42026-03-25 View
- 10-K2026-03-23 View
- 8-K2026-03-23 View
- 42026-03-16 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-13 View
- 42026-02-03 View
- 8-K2026-01-30 View
- 42026-01-26 View
- 42026-01-20 View
- 42026-01-20 View
- 42026-01-15 View
- 42026-01-15 View
- 42026-01-08 View
- 42026-01-08 View
- 42026-01-06 View
- 42026-01-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|